Pharma and life sciences: how a single patent offshore drives the US tax bill negative

Pharma's tax position turns on a property of the product that no other industry shares to the same degree. A single patent can be worth tens or hundreds of billions of dollars, because the entire value of a blockbuster drug is locked in a legal document, and that document can be held anywhere on earth. Put the patent in a zero-tax or low-tax country, have the US and European arms pay a royalty to use it, and the profit follows the patent offshore. The result is not just a low tax rate. In the largest cases it is a negative one: the US arm reports a loss and the giant draws a tax benefit. This page is about how the patent does that, and the numbers that prove it.

The underlying tool is the same offshore-held intellectual property and royalty machinery the tech sector uses, and several pharma groups ran the Double Irish and its successors. What is distinctive about pharma is the sheer concentration of value in one patent, the second lever of drug transfer pricing, and an outcome the other sectors rarely reach: a US tax liability below zero.

The signature lever: one patent, parked offshore

The classic structure puts ownership of the drug patent in a low-tax jurisdiction, Ireland at 12.5%, Bermuda at zero, or Puerto Rico under a favourable local regime, and then charges the operating companies in the US and Europe a royalty for the right to make and sell the drug. The US affiliates record large royalty expenses, which drive US taxable income down towards zero or below, while the offshore patent entity records the matching income and pays tax at a far lower rate.

The best-documented single example is on the public record through a US Senate Finance Committee investigation into a large US drugmaker. The company held dozens of patents for its best-selling immunology drug in Bermuda, which levies no corporate tax, and licensed rights back to its US operations through Irish subsidiaries. In 2020, more than 75% of the company's sales came from American consumers, yet only 1% of its income was reported in the United States for tax purposes. The Senate Finance Committee confirmed the company had continuously paid an effective tax rate less than half the US statutory rate of 21%, reporting rates of 8.7% for 2018, 8.6% for 2019 and 11.2% for 2020.

A figure that circulates needs careful handling, and we keep it separate. The same company's consolidated accounts for 2018 show a global effective tax rate of about negative 9.4%, meaning across the whole group it recorded a tax benefit rather than a charge that year, a one-off driven largely by US tax-reform transition effects. That negative 9.4% is the group's own filed GAAP rate; it is not the Senate's finding. The Senate's figure for 2018 was 8.7%. Both are real, they measure different things, and we never present the negative 9.4% as the Senate's number.

The second lever: pricing the drug itself

Running parallel to the royalty is the transfer price of the drug between a manufacturing affiliate and a distribution affiliate. A manufacturing entity in Puerto Rico or Singapore sells the drug to a US or European distributor at a price set to leave most of the profit in the low-tax country. This is legally distinct from the royalty, but it produces the same result: taxable income lands where the manufacturing entity sits, not where the sale or the original research happened. The same drug sells at very different prices in different countries, which gives this internal price unusual room to move. We treat this as a mechanism, not a stat: it is how the profit moves, and it compounds the royalty effect.

What the sector actually pays: below zero

Here is the figure that makes pharma distinct from every other sector on this site. In 2023, the major US drugmakers did not merely pay a low US rate; several reported US pre-tax losses while selling most of their drugs to Americans. The largest of them reported a US pre-tax loss of $4.4 billion, another a loss of $3.5 billion, a third a loss of $15.6 billion, and a fourth a loss of $2.0 billion. Taken together, the seven largest US pharmaceutical companies by revenue had a combined US tax liability in 2023 of negative $250 million. The Council on Foreign Relations summarised it plainly: the big US pharmaceutical companies have essentially stopped paying tax in the United States altogether.

By routing revenue through Irish subsidiaries, these firms pay around 12.5% in Ireland, well below the US rate, while exporting the products back to the US market. Ireland agreed to the OECD 15% global minimum in 2021, but the Pillar Two rules carve out substance-based income, a return on payroll and tangible assets, which preserves much of the advantage for companies with genuine Irish operations.

A secondary planning layer sits in Europe: the patent box. Several countries, including the UK at a 10% rate on qualifying IP profits, let a pharma company that is forced to hold IP in Europe rather than Bermuda still pay 10% rather than the headline rate. The UK patent box, introduced in 2013, applies a 10% corporation tax rate to profits from patented inventions.

Why your local pharmacy cannot do it

The signature lever needs a patent portfolio worth offshoring, operating companies in several countries to charge royalties to, and a manufacturing affiliate in a low-tax country to price the drug through. A community pharmacy, a small generics maker, or a biotech with a single early product has no such structure and nothing to gain from building one. The patent box rate is available in principle to a UK firm that genuinely patents an invention, and the nexus rule favours one that does its own research. But the offshore patent-and-royalty machine that drives a giant's US bill below zero is a tool of scale.